Emerging Threat: Rising Detection of Phenazolam and Desalkylgidazepam Phenazolam and Desalkylgidazepam are two designer benzodiazepines that were first reported as detected in the United States in 2022. Read more in our Frontline Alert here: aegislabs.com/news/nps-front…

A critical lab result. A quick call from a pharmacist. A life saved. This recent provider testimonial is a powerful reminder of how much impact collaboration can have in patient care.

"Don’t eat poppy seeds before a drug test!" Many have heard this, and maybe even laughed it off, but did you know it’s actually true? We explain how and why this happens and how to interpret these results in practice here: aegislabs.com/clinical-updat…

The threat of nitazenes to public health has gained congressional attention as a bill has been introduced to permanently place the entire class of nitazenes into Schedule I of the Controlled Substance Act. Read more here: nypost.com/2025/09/01/us-…

Please join our next webinar! Dr. Katie Liveoak will be discussing Opioid Use Disorder by providing evidence-based insights and practical strategies to help clinicians better understand, detect, and address recurrence risk. Register here: aegislabs.com/resources/webi…

ALERT: #Phenazolam, a dangerous #NPS in the Designer Benzodiazepine (DZBD) class, is rapidly emerging in illicit drug supplies and counterfeit pills. #AegisLabs ensures accurate identification of phenazolam and other DZBDs: aegislabs.com/services/novel… #Toxicology #PatientSafety

Please join us for an educational webinar session discussing Opioid Use Disorder (OUD). Dr. Liveoak will provide evidence-based insights and practical strategies to help clinicians better understand, detect, and address recurrence risk. Register Today: aegislabs.com/resources/webi…

Aegis offers validated testing for 7-hydroxymitragynine in both urine and oral fluid, helping clinicians detect exposure early and tailor care accordingly. Contact your Regional Sales Manager or visit: aegislabs.com/kratomtesting/. U.S. FDA takes action: fda.gov/news-events/pr…

Forty years after DEA HQ Agent Enrique ‘Kiki’ Camarena’s death, the DEA honors his legacy with the Red Ribbon Campaign each October. Learn more about the Red Ribbon Campaign below: - dea.gov/redribbon - getsmartaboutdrugs.gov #AegisLabs NPS menu: aegislabs.com

In this month's clinical update, we explore evidence-based insights and practical strategies to help clinicians better understand, detect, and address recurrence risk. Clinical Update: aegislabs.com/clinical-updat… #AegisLabs #OpioidUseDisorder #OpioidEpidemic #OpioidCrisis

Today is the DEA HQ National Rx #TakeBackDay. Starting at 10:00am, you can bring your expired, unneeded, and unwanted Rx medications to a participating collection site near you for safe disposal. Learn more here: dea.gov/takebackday #DEA #PublicSafety

The “fourth wave” of the opioid epidemic is defined by the combined use of illicit fentanyl with polysubstance use, particularly the rising combination of opioids and stimulants. More here: onlinelibrary.wiley.com/doi/epdf/10.11… Register for our upcoming webinar today: aegislabs.com/resources/webi…

This week, Kara KasaKaitas was awarded the ACS E. Ann Nalley Regional Award for Volunteer Service to the American Chemical Society for the Southeast Region. Aegis, along with the American Chemical Society, appreciate your leadership and contributions within Nashville, TN and the region.

#ICYMI: #AegisLabs Dr. Katie Liveoak discussed Opioid Use Disorder (OUD), return to use risks and more in our recent webinar. View on-demand: aegislabs.com/webinar/opioid…

In our recent webinar, Katie Liveoak, PharmD, BCPP from #AegisLabs shared expert insights on OUD, return to use risks, and how toxicology supports recovery. Watch this and explore our full library of recorded clinical presentations on our YouTube channel: youtube.com/@AegisSciences…

Tune in to our upcoming clinical webinar, where we will discuss new kratom variants composed of synthetic 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MP) and the importance of testing for them in high-risk populations. Register here: aegislabs.com/resources/webi…

Since implementation of our previous test update in June 2025, we have identified 9 new substances not previously detected in our lab. Learn more here: aegislabs.com/news/nps-front… #AegisLabs #NPSInsights #NPSSurveillance #PublicHealth #PatientCare #PublicSafety #DesignerDrugs

In this month's clinical update, we explore the emerging risk associated with the influx of #Kratom products in the market and how kratom use may impact #PatientCare and decision-making in clinical settings. Clinical Update: aegislabs.com/clinical-updat… #AegisLabs #Mitragynine #7OH

#Kratom continues to evolve, and many clinicians are encountering patients whose presentations don’t match what routine testing can detect. At #AegisLabs, we’re proud to offer comprehensive kratom testing and education to care teams across the nation. aegislabs.com/resources/webi…

A recent analysis of #7OH and mitragynine pseudoindoxyl products sold online found that 93% of these products were “mislabeled” or misleadingly marketed as traditional #kratom, despite these variants having 10 – 100x greater potency. #AegisLabs Webinar: aegislabs.com/webinar/kratom…